Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to MBF Bioscience in July, 2021 for $449,987.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43MH126834-01 | Phase I | 449,987 | July 9, 2021 | |||||||
A STTR Phase I contract was awarded to MBF Bioscience in July, 2021 for $760,219.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R42MH124566-01A1 | Phase I | 760,219 | July 2, 2021 | |||||||
A STTR Phase II contract was awarded to MBF Bioscience in August, 2022 for $994,964.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 4R42MH124566-02 | Phase II | 994,964 | August 18, 2022 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in May, 2020 for $1,313,060.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44MH116827-03 | Phase II | 1,313,060 | May 5, 2020 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in September, 2019 for $748,584.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44MH118815-02 | Phase II | 748,584 | September 17, 2019 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience in April, 2018 for $1,256,582.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44MH116827-01 | Phase I | 1,256,582 | April 1, 2018 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience in September, 2018 for $449,918.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44MH118815-01 | Phase I | 449,918 | September 17, 2018 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience in August, 2021 for $449,817.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43MH128076-01 | Phase I | 449,817 | August 19, 2021 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience in September, 2022 for $449,982.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44MH132234-01 | Phase I | 449,982 | September 5, 2022 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience in January, 2022 for $995,291.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44MH129023-01 | Phase I | 995,291 | January 1, 2022 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience in September, 2016 for $140,923.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43MH111540-01 | Phase I | 140,923 | September 1, 2016 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in July, 2015 for $1,497,001.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44MH108053-01 | Phase II | 1,497,001 | July 6, 2015 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in September, 2015 for $1,797,336.0 USD from the U.S. Department of Health & Human Services. | SBIR | 4R44MH105091-02 | Phase II | 1,797,336 | September 1, 2015 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in March, 2013 for $1,782,457.0 USD from the U.S. Department of Health & Human Services. | SBIR | 4R44MH093011-02 | Phase II | 1,782,457 | March 1, 2013 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in September, 2014 for $1,599,880.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44MH076188-05 | Phase II | 1,599,880 | September 17, 2014 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in September, 2016 for $2,360,602.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44MH093011-05 | Phase II | 2,360,602 | September 22, 2016 | |||||||
A SBIR Phase II contract was awarded to MBF Bioscience in August, 2016 for $1,499,395.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44MH099721-03 | Phase II | 1,499,395 | August 15, 2016 | |||||||
A SBIR Phase I contract was awarded to MBF Bioscience for $348,102.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44MH105091-01 | Phase I | 348,102 | ||||||||
A SBIR Phase I contract was awarded to MBF Bioscience for $99,933.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43MH095343-01 | Phase I | 99,933 | ||||||||
A SBIR Phase II contract was awarded to MBF Bioscience for $806,072.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44MH085337-02A1 | Phase II | 806,072 | ||||||||
A SBIR Phase II contract was awarded to MBF Bioscience for $744,130.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44ES017180-02 | Phase II | 744,130 | ||||||||
A SBIR Phase II contract was awarded to MBF Bioscience for $1,599,880.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44MH076188-05 | Phase II | 1,599,880 | ||||||||
A SBIR Phase I contract was awarded to MBF Bioscience for $149,974.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43MH097366-01 | Phase I | 149,974 | ||||||||
A SBIR Phase I contract was awarded to MBF Bioscience for $272,040.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43MH083352-01A1 | Phase I | 272,040 | ||||||||
A SBIR Phase I contract was awarded to MBF Bioscience for $100,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43MH076188-01 | Phase I | 100,000 |